240 citations
Counting papers with at most 25 authors, so collaboration author lists do not stand in for the people here.
- Universitätsmedizin GöttingenDE13 papers
- Medical University of ViennaAT10 papers
- Roche (Switzerland)CH10 papers
- University of GöttingenDE9 papers
- Pfizer (United States)US6 papers
- Tris Pharma (United States)US6 papers
- Lancaster UniversityGB5 papers
- MRC Biostatistics UnitGB5 papers
- Novartis (United States)US5 papers
- University Hospital MagdeburgDE5 papers
- Boehringer Ingelheim (Germany)DE4 papers
- Newcastle UniversityGB4 papers
3 papers · 2 filters
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) -- estimation of adverse event risks
Regina Stegherr, Claudia Schmoor, Jan Beyersmann +12
The SAVVY project aims to improve the analyses of adverse event (AE) data in clinical trials through the use of survival techniques appropriately dealing with varying follow-up tim…
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) -- comparison of adverse event risks in randomized controlled trials
Kaspar Rufibach, Regina Stegherr, Claudia Schmoor +12
Analyses of adverse events (AEs) are an important aspect of the evaluation of experimental therapies. The SAVVY (Survival analysis for AdVerse events with Varying follow-up times)…
Principal Stratum Strategy: Potential Role in Drug Development
Björn Bornkamp, Kaspar Rufibach, Jianchang Lin +6
A randomized trial allows estimation of the causal effect of an intervention compared to a control in the overall population and in subpopulations defined by baseline characteristi…